# To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

> **NCT04814056** · PHASE4 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 15 (estimated)

## Conditions studied

- NRG1-fused Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Afatinib Dimaleate

## Key facts

- **NCT ID:** NCT04814056
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2023-09-29
- **Final completion:** 2024-01-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04814056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04814056, "To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04814056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*